243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection
The Readout Loud
00:00
Lilly Drug - What's the Difference?
Lilly's drug is designed to allow patients to stop taking it if they sufficiently lower amyloid levels. That was a reason given for why there weren't enough patients to get to this milestone the FDA was looking for. Of course, A-size and biogen's drug was approved on that same accelerated approval basis,. But the difference was they'd already reported out that phase three outcomes trial.
Play episode from 04:14
Transcript
